CYPATH LUNG


Associated tags: Lung cancer, Survival, Patient, Data analysis, Clinical trial, Disease, Flow cytometry, Cancer, TCPP, Lung, Malignancy, Biotechnology, BIAF, Health, Clinical Trials, Oncology, Genetics, Medical Devices, Medical imaging, Pharmaceutical, FDA, General Health, Other Health, Physician, COPD, Hospital, Surgery, Radiology

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

Retrieved on: 
Wednesday, April 24, 2024
Other Defense, FDA, Other Health, Radiology, Pharmaceutical, Surgery, Oncology, Medical Devices, Defense, Genetics, Military, Clinical Trials, Biotechnology, Science, Research, Health, Doctor of Philosophy, University, Chronic obstructive pulmonary disease, Lung cancer, DOD, Prognosis, University of Texas System, Artificial intelligence, Sputum, Molecular and Cellular Biology, BIAF, Lung, Patient, Principal, Observational study, Cellular senescence, New product development, Biopsy, BAMC, Bronchoalveolar lavage, BAL, COPD, Medical imaging

The second test under development analyzes sputum to improve detection of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • The second test under development analyzes sputum to improve detection of chronic obstructive pulmonary disease (COPD).
  • COPD is an inflammatory lung disease that causes breathing-related problems and irreversible airflow obstruction for an estimated 16 million Americans, according to the Centers for Disease Control.
  • Dr. Elzi earned his Ph.D. in Molecular and Cellular Biology from the University of Washington, in conjunction with the Fred Hutchinson Cancer Research Center.
  • He subsequently performed post-doctoral research at the Bonfils Blood Center and University of Colorado Department of Surgery, where he studied the molecular mechanisms of transfusion-related lung injury.

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

Retrieved on: 
Tuesday, April 9, 2024
Other Health, Research, Pharmaceutical, Philanthropy, Oncology, Medical Devices, Genetics, Foundation, Clinical Trials, Science, Biotechnology, Health, QI, Lung cancer, Survival, Partnership, Risk, American Cancer Society, Cancer, Lung, BIAF, ACS, Map, Mobile phone

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.
  • Initially launched in November 2023 to support local lung cancer screening, bioAffinity Technologies and its ACS South Region partner have expanded the geographic reach to include ACS Lung QI sites across the country.
  • The campaign highlights the value of early screening and provides information about bioAffinity Technologies’ CyPath® Lung , a noninvasive test to improve early detection of lung cancer.
  • The ACS website has an interactive map that helps people eligible for screening find a cancer screening location near them.

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Medical Devices, Surgery, FDA, Genetics, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Research, Lung cancer, Growth, CFO, Laboratory developed test, Form, Patient, Accounting, Bronchoalveolar lavage, Sale, Acquisition, Cancer, CPA, CAP, Insurance, MBA, Lung, BAL, BIAF, Bronchoscopy, LDT, Optimism, Medicare, Calendar, Marketing, CMS, Physician, Pharmaceutical industry

Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
  • Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
  • Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
  • Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Retrieved on: 
Friday, March 8, 2024
Research, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, BIAF, Suite, Sale, Exercise, Regulation D, Form, Offering, Security (finance)

The gross proceeds to the Company from the offering are expected to be approximately $2.5 million, before deducting underwriter fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from the offering are expected to be approximately $2.5 million, before deducting underwriter fees and other offering expenses payable by the Company.
  • The common stock was issued in a registered direct offering pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The common warrants will be issued in a concurrent private placement.
  • A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov .

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Retrieved on: 
Wednesday, March 6, 2024
Research, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, BIAF, Suite, Sale, Exercise, Regulation D, Form, Offering, Security (finance)

The closing of the offering is expected to occur on or about March 8, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about March 8, 2024, subject to the satisfaction of customary closing conditions.
  • The common stock will be issued in a registered direct offering pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The common warrants will be issued in a concurrent private placement.
  • A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC and available on the SEC’s website located at http://www.sec.gov .

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

Retrieved on: 
Tuesday, March 5, 2024
Research, Medical Devices, Hospitals, Genetics, Clinical Trials, Biotechnology, Health, Science, Oncology, BIAF, Lung cancer, Pulmonology, Disease, Lung, Growth, Diagnosis, Risk, Medical imaging

CyPath® Lung is a noninvasive test to detect early-stage lung cancer.

Key Points: 
  • CyPath® Lung is a noninvasive test to detect early-stage lung cancer.
  • bioAffinity Technologies is on target to meet its sales forecast for the previously announced limited test market launch in Texas designed to refine future positioning and strategic insight for CyPath® Lung in preparation for expanding to the national market.
  • bioAffinity Technologies' commitment to noninvasive cancer detection is poised to reshape the landscape of lung health management by increasing early detection and treatment.
  • bioAffinity Technologies will release financial results for the fourth quarter and full year ended December 31, 2023, on April 1, 2024.

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

Retrieved on: 
Tuesday, February 6, 2024
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Surgery, Artificial Intelligence, Oncology, Research, Medical Devices, Genetics, Health Technology, Science, Clinical Trials, Coagulation, Patient, BIAF, Lung cancer, Medicine, Cryotherapy, Physician, Lung, Plasma

Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath® Lung into its practice to aid in the detection of early-stage lung cancer.

Key Points: 
  • Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath® Lung into its practice to aid in the detection of early-stage lung cancer.
  • “As a clinician, I see hundreds of patients a year who can directly benefit from CyPath® Lung, bioAffinity’s patient-friendly, noninvasive test for lung cancer.
  • As a researcher, I am excited about the Company’s ongoing studies to advance CyPath® Lung, as well as noninvasive tests for other lung diseases,” Dr. Bansal said.
  • Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board.

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Surgery, Artificial Intelligence, Oncology, Research, Medical Devices, Genetics, Health Technology, Science, Clinical Trials, Liquid biopsy, Lung, BIAF, NeoGenomics, Labcorp, Genomics, Quest Diagnostics, Genomics England, Lung cancer, Roche, Growth, NGS, Hospital, Management

Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets.

Key Points: 
  • Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets.
  • Under her leadership, the company raised a Series A funding and enhanced the board with expertise from U.S. and international markets.
  • "I am deeply honored to join the bioAffinity Technologies Board of Directors," Dr. Platt said.
  • Dr. Platt replaces Mohsin Y. Meghji who stepped down from the Board of Directors on Dec. 1, 2023, after serving four years.

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

Retrieved on: 
Wednesday, November 15, 2023
Other Health, General Health, Pharmaceutical, Philanthropy, Oncology, Medical Devices, Genetics, Fund Raising, Clinical Trials, Biotechnology, FDA, Health, Lung, BIAF, Quality, American Cancer Society, ACS, Patient, Multimedia, Lung cancer, University, MD, Cancer, Partnership, Medical imaging, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership with the American Cancer Society (ACS) to increase lung cancer screening in Texas.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership with the American Cancer Society (ACS) to increase lung cancer screening in Texas.
  • View the full release here: https://www.businesswire.com/news/home/20231115775728/en/
    A partnership to improve lung cancer screening.
  • The campaign highlights the work of ACS and UT Health and provides information about bioAffinity Technologies’ CyPath® Lung , a noninvasive test to improve early detection of lung cancer.
  • “Early detection of cancer saves lives, and screening for cancer – particularly lung cancer – is powerful.

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

Retrieved on: 
Monday, November 6, 2023
Oncology, Health, Health Technology, Clinical Trials, General Health, Biotechnology, Water, Pulmonology, Lymph, BIAF, Physician, Lung cancer, Organization, Emphysema, Quality of life, National Directorate of Intelligence and Prevention Services, Lung, Marketing, Hospital, Hygiene, Patient, Diagnosis, COPD, Bronchoscopic lung volume reduction, Medical imaging, Ecolab

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales.
  • Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America’s therapeutic solutions division.
  • Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities.
  • “We are delighted to welcome Dallas to our management team in this newly created position.